- Details
- Description
-
Packaging Size14t/bottle
-
Strength4.5mg
-
CompositonPemigatinib
-
TreatmentFLT3+ holangiocarcinoma,Myeloid or Lymphoid Neoplasms
-
FormTablet
-
BrandLuciPem
-
Quantity Unit4.5mg*14t/bottle
-
ManufacturerLUCIUS PHARMACEUTICAL,Laos PDR
Pemigatinib is a type of targeted cancer drug. It is a treatment for bile duct cancer that has come back or spread to other parts of the body. This is advanced bile duct cancer. called Fibroblast Growth Factor Receptor 2 (FGFR2).
Cholangiocarcinoma
Indicated for unresectable locally advanced or metastatic cholangiocarcinoma in previously treated patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement
Each cycle is 21 days
13.5 mg PO qDay for 14 consecutive days followed by 7 days off therapy
Continue until disease progression or unacceptable toxicity occurs
Myeloid or Lymphoid Neoplasms
Indicated for relapsed or refractory myeloid/lymphoid neoplasms (MLNs) in adults with fibroblast growth factor receptor 1 (FGFR1) rearrangement
13.5 mg PO qDay
Continue until disease progression or unacceptable toxicity occur
